NEXALIS THERAPEUTICS LTD

0.023

+0.00421.05%

Volume:34.08K

Turnover:774.00

Market Cap:5.82M

PE:-3.06

High:0.023

Open:0.020

Low:0.020

Close:0.019

52wk High:0.048

52wk Low:0.017

Shares:253.04M

Float Shares:63.39M

Volume Ratio:4.65

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.008

EPS(LYR):-0.008

ROE:--

ROA:-86.71%

PB:-6.12

PE(LYR):-3.06

Loading ...

Overview Company News Filings

BUZZ-Australia's Nexalis Therapeutics gains most in over 6 months on trial approval

Reuters

·

2 hours ago

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NX1.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NX1.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NX1.AU\",,,,,undefined,":{"symbol":"NX1.AU","market":"AU","secType":"STK","nameCN":"NEXALIS THERAPEUTICS LTD","latestPrice":0.023,"timestamp":1776406320000,"preClose":0.019,"halted":0,"volume":34079,"delay":0,"changeRate":0.2105263157894737,"nameEN":"NEXALIS THERAPEUTICS LTD","floatShares":63391198,"shares":253037323,"eps":-0.00751,"marketStatus":"Closed","change":0.004,"latestTime":"04-17 16:12:00 AEST","open":0.02,"high":0.023,"low":0.02,"amount":774,"amplitude":0.157895,"askPrice":0.024,"askSize":116697,"bidPrice":0.021,"bidSize":47619,"shortable":3,"etf":0,"ttmEps":-0.00751,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1776643200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.019,"openAndCloseTimeList":[[1776384000000,1776405600000]],"volumeRatio":4.645067,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NX1.AU","preClose":0.019,"auctionPrice":0.02,"auctionVolume":83,"auctionTime":1776405604143,"referencePrice":0.023,"referenceTime":1776408120447,"auction":3,"marketStatus":"盘后竞价","timestamp":1776405604143}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NX1.AU\",,,,,undefined,":{"symbol":"NX1.AU","floatShares":63391198,"roa":"-86.71%","roe":"--","lyrEps":-0.00751,"volumeRatio":4.645067,"shares":253037323,"dividePrice":0,"high":0.023,"amplitude":0.157895,"preClose":0.019,"low":0.02,"week52Low":0.017,"pbRate":"-6.12","psRate":"5.90","week52High":0.048,"institutionHeld":0,"latestPrice":0.023,"committee":-0.420397,"eps":-0.00751,"divideRate":0,"volume":34079,"delay":0,"ttmEps":-0.00751,"open":0.02,"prevYearClose":0.024,"prevWeekClose":0.018,"prevMonthClose":0.02,"prevQuarterClose":0.02,"fiveDayClose":0.018,"twentyDayClose":0.025,"sixtyDayClose":0.023},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NX1.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NX1.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NX1.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2628220397","title":"BUZZ-Australia's Nexalis Therapeutics gains most in over 6 months on trial approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2628220397","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628220397?lang=en_us&edition=fundamental","pubTime":"2026-04-17 14:01","pubTimestamp":1776405719,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Nexalis Therapeutics gains most in over 6 months on trial approval** Shares of Australia's Nexalis Therapeutics NX1.AX rise as much as 21.1% to A$0.023, their biggest intraday pct gain since October 9, 2025** Stock touches its highest level since March 26** The clinical stage drug developer receives an approval from Australian health regulator Safety Review Committee  for a second trial for dosing of acute pain reliever, IRX-616a** Stock up 27.8% so far this week, set for its best week in over a year, if gains hold** Despite moves, stock down 4.2% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nL6N4100C7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NX1.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":1,"code":"91000000","status":"200"}]}}